Explore the categories so you can find more about your search.

Categorie > Cancer / Oncology

Routinely Used Diagnostic Approaches: Only Limited Diagnostic Sensitivity For Bile Duct Cancer?

Categorie : Cancer / Oncology
Surgery is the only curative treatment in patients with bile duct cancer. To develop a therapeutic concept a reliable diagnostic procedure is of great importance in these patients. Due to longitudinal tumor growth along the bile duct, imaging techniques including ultrasound, computed tomography, an ...

read more Surgery is the only curative treatment in patients with bile duct cancer. To develop a therapeutic concept a reliable diagnostic procedure is of great importance in these patients. Due to longitudinal tumor growth along the bile duct, imaging techniques including ultrasound, computed tomography, an read more Mon Mar 2008 Mon Mar 2008

Are The Progression To Esophageal Cancer And Increased Slug Expression Linked?

Categorie : Cancer / Oncology
Real-time reverse transcription-polymerase chain reaction (RT-PCR), semi-quantitative immunohistochemistry and tissue array reveal that the progression to adenocarcinoma is associated with increased Slug expression and this may represent a mechanism of E-cadherin silencing.This study, performed by ...

read more Real-time reverse transcription-polymerase chain reaction (RT-PCR), semi-quantitative immunohistochemistry and tissue array reveal that the progression to adenocarcinoma is associated with increased Slug expression and this may represent a mechanism of E-cadherin silencing.This study, performed by read more Mon Mar 2008 Mon Mar 2008

Clavis Pharma Announces Expansion Of ELACYT(TM) Clinical Development Program

Categorie : Cancer / Oncology
Clavis Pharma (OSE: CLAVIS) announced that it has received approval from the Belgian Authorities to initiate a new Phase II clinical study with ELACYT(TM) in ovarian cancer at the University Hospital of Leuven, with Professor Ignace Vergote as principal investigator. The study has also been approved ...

read more Clavis Pharma (OSE: CLAVIS) announced that it has received approval from the Belgian Authorities to initiate a new Phase II clinical study with ELACYT(TM) in ovarian cancer at the University Hospital of Leuven, with Professor Ignace Vergote as principal investigator. The study has also been approved read more Mon Mar 2008 Mon Mar 2008

Vitamin And Mineral Supplement Use Among US Adults After Cancer Diagnosis: A Systematic Review

Categorie : Cancer / Oncology
UroToday.com - Many of the 10 million cancer patients in the US are taking nutritional supplements, but an accurate assessment of the frequency is not well appreciated. In the February 1, 2008 issue of the Journal of Clinical Oncology, Christine Velicer and Cornelia Ulrich report a systematic revie ...

read more UroToday.com - Many of the 10 million cancer patients in the US are taking nutritional supplements, but an accurate assessment of the frequency is not well appreciated. In the February 1, 2008 issue of the Journal of Clinical Oncology, Christine Velicer and Cornelia Ulrich report a systematic revie read more Mon Mar 2008 Mon Mar 2008

Sensitivity Of Normal, Paramalignant, And Malignant Human Urothelial Cells To Inhibitors Of The Epidermal Growth Factor Receptor Signaling Pathway

Categorie : Cancer / Oncology
UroToday.com - Starting from a well-established cell culture system of normal human urothelial cells (1,2), the epithelial cells that line the bladder, we used retroviral transduction to generate "designer" cell lines with specific molecular alterations. These "paramalignant" human urothelial cell s ...

read more UroToday.com - Starting from a well-established cell culture system of normal human urothelial cells (1,2), the epithelial cells that line the bladder, we used retroviral transduction to generate read more Mon Mar 2008 Mon Mar 2008

External Validation Of IMP3 Expression As An Independent Prognostic Marker For Metastatic Progression And Death For Patients With Renal Carcinona

Categorie : Cancer / Oncology
UroToday.com - This trial was a validation of IMP3 as marker for the aggressiveness of renal cell carcinoma. It confirmed that IMP3 positivity can predict increased metastasis and decreased survival in renal cell carcinoma patients.Validation studies are not widely performed or reported on biomarke ...

read more UroToday.com - This trial was a validation of IMP3 as marker for the aggressiveness of renal cell carcinoma. It confirmed that IMP3 positivity can predict increased metastasis and decreased survival in renal cell carcinoma patients.Validation studies are not widely performed or reported on biomarke read more Mon Mar 2008 Mon Mar 2008

2008 AACR-Bardos Awards For Undergraduate Students Announced

Categorie : Cancer / Oncology
To foster interest in cancer research careers among the next generation of young scientists, the AACR will provide an opportunity for 10 undergraduate students to experience the field first hand at its Annual Meeting 2008 through the AACR-Thomas J. Bardos Science Education Awards for Undergraduate S ...

read more To foster interest in cancer research careers among the next generation of young scientists, the AACR will provide an opportunity for 10 undergraduate students to experience the field first hand at its Annual Meeting 2008 through the AACR-Thomas J. Bardos Science Education Awards for Undergraduate S read more Mon Mar 2008 Mon Mar 2008

Studies Review New Drug And Indications For Heated Chemotherapy

Categorie : Cancer / Oncology
Studies have shown that surgery combined with Intraperitoneal Hyperthermic Chemotherapy (IPHC) can improve survival rates for select patients with peritoneal carcinoma (cancer of the lining of the abdominal cavity) that has spread from colorectal or appendix cancer. ...

read more Studies have shown that surgery combined with Intraperitoneal Hyperthermic Chemotherapy (IPHC) can improve survival rates for select patients with peritoneal carcinoma (cancer of the lining of the abdominal cavity) that has spread from colorectal or appendix cancer. read more Mon Mar 2008 Mon Mar 2008

Soy Compound May Halt Spread Of Prostate Cancer

Categorie : Cancer / Oncology
A compound found in soybeans almost completely prevented the spread of human prostate cancer in mice, according to a study published in the March 15 issue of Cancer Research, a journal of the American Association for Cancer Research. Researchers say that the amount of the chemical, an antioxidant kn ...

read more A compound found in soybeans almost completely prevented the spread of human prostate cancer in mice, according to a study published in the March 15 issue of Cancer Research, a journal of the American Association for Cancer Research. Researchers say that the amount of the chemical, an antioxidant kn read more Mon Mar 2008 Mon Mar 2008

Toxin Found In Leading Organic Brands

Categorie : Cancer / Oncology
A new study commissioned by a US consumer watchdog found that leading brands of personal care products such as shampoos, lotions and body washes that are labelled organic or 100 per cent natural contain an unidisclosed carcinogenic toxin 1,4-Dioxane. The tests were carried out by a well known, repu ...

read more A new study commissioned by a US consumer watchdog found that leading brands of personal care products such as shampoos, lotions and body washes that are labelled organic or 100 per cent natural contain an unidisclosed carcinogenic toxin 1,4-Dioxane. The tests were carried out by a well known, repu read more Mon Mar 2008 Mon Mar 2008

Roswell Park Cancer Institute Receives Grant To Develop Vaccine Against Ovarian Cancer

Categorie : Cancer / Oncology
The Ovarian Cancer Research Fund awarded a $900,000 research grant to Kunle Odunsi, MD, Department of Gynecologic Oncology, and team at Roswell Park Cancer Institute (RPCI) to collaborate on developing a promising vaccine to unleash the power of the immune system against cancer. The prestigious awar ...

read more The Ovarian Cancer Research Fund awarded a $900,000 research grant to Kunle Odunsi, MD, Department of Gynecologic Oncology, and team at Roswell Park Cancer Institute (RPCI) to collaborate on developing a promising vaccine to unleash the power of the immune system against cancer. The prestigious awar read more Mon Mar 2008 Mon Mar 2008

Calando Files IND For SiRNA Nanoparticle Therapeutic In Oncology

Categorie : Cancer / Oncology
Calando Pharmaceuticals, a leading siRNA therapeutics company, announced that the company has submitted an investigational new drug application (IND) to the U.S. Food and Drug Administration (FDA) to initiate a Phase I clinical trial using their lead anti-cancer compound, CALAA-01. ...

read more Calando Pharmaceuticals, a leading siRNA therapeutics company, announced that the company has submitted an investigational new drug application (IND) to the U.S. Food and Drug Administration (FDA) to initiate a Phase I clinical trial using their lead anti-cancer compound, CALAA-01. read more Mon Mar 2008 Mon Mar 2008

Hawthorn Pharmaceuticals, Inc. Receives FDA Approval On Granisol? Oral Solution

Categorie : Cancer / Oncology
Hawthorn Pharmaceuticals, Inc. announced the US Food and Drug Administration (FDA) approval of the company's Granisol? (granisetron HCl) Oral Solution. Granisol? is an oral solution for the prevention of nausea and vomiting associated with cancer therapy. Granisol? is the AA-rated equivalent of Roch ...

read more Hawthorn Pharmaceuticals, Inc. announced the US Food and Drug Administration (FDA) approval of the company's Granisol? (granisetron HCl) Oral Solution. Granisol? is an oral solution for the prevention of nausea and vomiting associated with cancer therapy. Granisol? is the AA-rated equivalent of Roch read more Mon Mar 2008 Mon Mar 2008

Sunesis Pharmaceuticals Reports Positive Interim Data For SNS-595 Single-Agent Activity In Platinum-Resistant Ovarian Cancer

Categorie : Cancer / Oncology
Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel small-molecule therapeutics, announced positive interim data from the company's ongoing Phase 2 clinical trial of its lead product candidate, ...

read more Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel small-molecule therapeutics, announced positive interim data from the company's ongoing Phase 2 clinical trial of its lead product candidate, read more Wed Mar 2008 Wed Mar 2008

Vermillion's Biomarkers Prove Beneficial In Identifying Women With Ovarian Cancer And Detecting Early Stage Disease

Categorie : Cancer / Oncology
Vermillion, Inc. (Nasdaq: VRMLD), a molecular diagnostics company, presented data from several studies demonstrating the benefits of the Company's ovarian cancer protein biomarker panel. The data suggest that use of Vermillion's biomarkers could help better identify women with ovarian cancer, as w ...

read more Vermillion, Inc. (Nasdaq: VRMLD), a molecular diagnostics company, presented data from several studies demonstrating the benefits of the Company's ovarian cancer protein biomarker panel. The data suggest that use of Vermillion's biomarkers could help better identify women with ovarian cancer, as w read more Wed Mar 2008 Wed Mar 2008

Recurrent Low-Grade Carcinoma Of The Ovary Less Responsive To Chemo Than More Common Ovarian Cancers

Categorie : Cancer / Oncology
Recurrent low-grade serous carcinoma, a rare type of ovarian cancer, is less sensitive to chemotherapy and therefore more difficult to treat than more common high-grade ovarian cancers, according to researchers from The University of Texas M. D. Anderson Cancer Center. The findings were reported at ...

read more Recurrent low-grade serous carcinoma, a rare type of ovarian cancer, is less sensitive to chemotherapy and therefore more difficult to treat than more common high-grade ovarian cancers, according to researchers from The University of Texas M. D. Anderson Cancer Center. The findings were reported at read more Wed Mar 2008 Wed Mar 2008

The Importance Of Testing For BRCA1/2 Mutations In Women With Ovarian Cancer

Categorie : Cancer / Oncology
Majority of women with ovarian cancer unaware BRCA testing is availableTwo abstracts underscoring the importance of testing for BRCA1/2 mutations in women with ovarian cancer were presented at this week's Society of Gynecologic Oncologists 39th Annual Meeting on Women's Cancers, by researchers from ...

read more Majority of women with ovarian cancer unaware BRCA testing is availableTwo abstracts underscoring the importance of testing for BRCA1/2 mutations in women with ovarian cancer were presented at this week's Society of Gynecologic Oncologists 39th Annual Meeting on Women's Cancers, by researchers from read more Wed Mar 2008 Wed Mar 2008

GSK Cervical Cancer Candidate Vaccine Cervarix(R) Demonstrates Long-Term Protection For More Than Six Years

Categorie : Cancer / Oncology
New data demonstrate that GlaxoSmithKline's (NYSE: GSK) cervical cancer candidate vaccine, CERVARIX provides significant protection for women against the four most common cancer-causing human papillomavirus types for nearly six and a half years, the longest duration of protection reported to date. ...

read more New data demonstrate that GlaxoSmithKline's (NYSE: GSK) cervical cancer candidate vaccine, CERVARIX provides significant protection for women against the four most common cancer-causing human papillomavirus types for nearly six and a half years, the longest duration of protection reported to date. read more Wed Mar 2008 Wed Mar 2008

Anavex 7-1037 Reduces Reduced Tumor Growth By 69% In Pre-Clinical Studies

Categorie : Cancer / Oncology
Anavex Life Sciences Corp. ("ANAVEX") (OTCBB: AVXL) announced that ANAVEX 7-1037 has demonstrated its ability to significantly delay the growth of cancerous tumors in patient-derived xenografts during advanced pre-clinical studies. The human tumor xenografts were developed in ANAVEX labs using a sam ...

read more Anavex Life Sciences Corp. ( read more Wed Mar 2008 Wed Mar 2008

Local Researchers Look To Improve Treatment For Lung Cancer Patients, UK

Categorie : Cancer / Oncology
Doctors from around the UK are taking part in one of the world's largest lung cancer clinical trials investigating how a blood thinning drug might help prevent blood clots in lung cancer patients. The Cancer Research UK funded trial - named ...

read more Doctors from around the UK are taking part in one of the world's largest lung cancer clinical trials investigating how a blood thinning drug might help prevent blood clots in lung cancer patients. The Cancer Research UK funded trial - named read more Wed Mar 2008 Wed Mar 2008

<<< previous | 1 | 2 | 3 | 4 | 5 | 6 | 7 next >>>



     


Custom Search